Posters
(results will display both Free Papers & Poster)
Pseudo-accommodative IOLs for pseudophakic presbyopia
Poster Details
First Author: M. Dvali GEORGIA
Co Author(s): N. Tsintsadze B. Sirbiladze L. Vardnashvili
Abstract Details
Purpose:
To access uncorrected visual acuity on different distances keeping binocularity after implantation of pseudoaccommodative IOL in both eyes with planned target amizometropia
Setting:
Tbilisi State Medical University, Eye Clinic 'Akhali Mzera'
Methods:
Emetropia achieved with pseudoaccommodative IOL doesn’t allow patients to work/read without correction. Monovision (-2,5-3,0D) excludes binocularity. Pseudoaccommodative IOLs (Tetraflex/Lenstec) we use move forward together with capsular bag by 0.5-0.7 mm changing the refraction maximum by 1.5D, not enough for working for near. We use pseudoaccommodative minimonovision with difference between eyes 1,25-1,5D, the dominant eye, corrected for far has emmetropic refraction, fellow eye – low myopia refraction, without loss of binocularity. Working at near distance – dominant eye has low myopia upto-1,5D, fellow eye -3,0D that also keeps binocularity. Difference 1,25-1,5D between eyes is also kept when working on medium distances.
Results:
The 74 eyes undergone pseudoaccomodative IOLs (Tetraflex) implantation. All the patients have from 1.25 to 1.5 D anisocorrection to achieve pseudophakic minimonovision. The follow up period was from 3 months to 3 years. Mean distance UCVA was 20/35 or better, mean UCVA for near was J2 and 20/35 - for intermediate distance, group 2 achieved mean UCVA for near – J1; UCVA intermediate was J5.
Conclusions:
Satisfactory UCVA for all distances (near, intermediate, far) was achieved in all patients. Proper patients' selection,their extensive education, precise calculation to get minimal differences (1.25-1.5 D) between eyes are crucial to success of pseudoaccommodative minimonovision. Further prospective long-term studies will show the viability of this method to find its place in refractive surgery.
Financial Disclosure:
None